8-K: Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Polycythemia Vera

Protagonist Therapeutics and Takeda report positive topline results from the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera, meeting the primary endpoint and all key secondary endpoints.

Summary

• Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study of rusfertide for polycythemia vera (PV).
• The study met its primary endpoint, with 77% of rusfertide-treated patients achieving a clinical response compared to 33% in the placebo group (p<0.0001).
• All four key secondary endpoints were met, including the EU primary endpoint, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 in the placebo arm (p<0.0001).
• Other secondary endpoints, including hematocrit control and patient-reported outcomes (PROMIS Fatigue SF-8a and MFSAF TSS-7), were also achieved with statistical significance.
• Rusfertide was generally well tolerated, with safety in line with previous studies and no new safety findings observed.
• The majority of adverse events were grade 1-2 injection site reactions, and all serious adverse events were deemed not drug-related.
• There was no evidence of an increased risk of cancer in rusfertide-treated patients compared to those on placebo.
• Protagonist will receive a $25 million milestone payment from Takeda following completion of the VERIFY clinical study report.
• The companies plan to submit additional details of these results for presentation at upcoming medical conferences in 2025.
• Protagonist expects to file a New Drug Application (NDA) in Q4 2025.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 3 clinical trial, suggesting a high likelihood of regulatory approval and commercial success. The achievement of primary and secondary endpoints, coupled with a favorable safety profile, contributes to a very positive sentiment.

Positives

• The primary endpoint of the VERIFY study was met with statistical significance (p<0.0001).
• All four key secondary endpoints were met, including the EU primary endpoint.
• Rusfertide demonstrated a favorable safety profile, consistent with previous studies.
• Protagonist is set to receive a $25 million milestone payment from Takeda.
• The results support the potential for rusfertide to address unmet medical needs in PV patients.
• The company expects to file an NDA in Q4 2025.

Negatives

• The document does not explicitly state any negatives.
• The study focuses on patients who are phlebotomy-dependent despite standard of care, indicating a population with existing challenges in managing their condition.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of NDA filing and regulatory approval is not guaranteed.
• The commercial success of rusfertide depends on various factors, including market competition and acceptance.

Future Outlook

Protagonist plans to submit additional details of the VERIFY study results for presentation at upcoming medical conferences in 2025 and expects to file an NDA in Q4 2025.

Management Comments

• Arturo Molina, M.D., M.S., Chief Medical Officer of Protagonist, stated that the results provide compelling evidence of the potential for rusfertide to address unmet medical needs in patients with PV.
• Andy Plump, M.D., Ph.D., President of R&D at Takeda, expressed excitement about the potential of rusfertide to help patients living with PV.
• Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist, noted that the study results mark a critical inflection point in Protagonist's hepcidin program and further validates their platform.

Industry Context

Polycythemia vera is a rare blood disorder with limited treatment options, and rusfertide represents a potential first-in-class erythrocytosis-specific agent. The positive results could position Protagonist and Takeda favorably in the hematology market.

Comparison to Industry Standards

• Current treatments for PV often involve phlebotomy and cytoreductive therapies like hydroxyurea and ruxolitinib.
• The VERIFY study results suggest that rusfertide could reduce the need for phlebotomy and improve hematocrit control compared to placebo.
• Comparable companies in the hematology space include Incyte (developer of ruxolitinib) and other firms focused on blood cancer treatments.
• The achievement of key secondary endpoints, including patient-reported outcomes, highlights the potential for rusfertide to improve the quality of life for PV patients, which is a significant unmet need.

Stakeholder Impact

• Shareholders: Positive results may lead to increased stock value.
• Patients: Rusfertide offers a potential new treatment option for polycythemia vera.
• Employees: Successful development and commercialization could lead to job security and growth.
• Takeda: The collaboration strengthens their pipeline in hematology.

Next Steps

• Submit additional details of the VERIFY study results for presentation at upcoming medical conferences in 2025.
• File a New Drug Application (NDA) in Q4 2025.

Key Dates